CLINICAL, BIOCHEMICAL, AND NEUROIMAGING ASPECTS OF MIGRAINE DYNAMICS IN CHILDREN AND ADOLESCENTS
Keywords:
cephalalgia, migraine, children, adolescents, diagnosisAbstract
Migraine is one of the most common neurological disorders, affecting 7.7% of children and adolescents in the general population. The disease may manifest as early as under three years of age. As children grow older, the prevalence of migraine increases, reaching up to 15% in adolescence. Migraine significantly reduces a child’s daily activity and academic performance. Diagnosing migraine in children presents certain challenges and often leads to misdiagnosis and, consequently, inadequate treatment. Therefore, in pediatric neurology, special attention is currently being paid to the development and implementation of early diagnostic methods and reliable approaches for monitoring the course of this condition.
References
Алиджанова Д.А. Клинико-неврологические и иммунологические аспекты мигрени у детей. // Дисс на соиск. уч. ст. канд. мед. наук. Ташкент – 2020.
Sakai F., Hirata K., Igarishi H., et al. A study to investigate the prevalence of headache disorders and migraine among people registered in a health insurance association in Japan. J. Headache Pain. 2022; 23 (1): 70.
Делягин В.М., Московцева Ж.М., Аксенова Н.С. Мигрень: педиатрические аспекты. Эффективная фармакотерапия. 2023; 19
(17): 14–21. DOI 10.33978/2307-3586-2023-19-17-14-21.
Miglis M. Migraine and autonomic dysfunction: which is the horse and which is the jockey? Curr. Pain Headache Rep. 2018; 22 (3).
Hautakangas H., Winsvold B., Ruotsalainen S., et al. Genome-wide analysis of 102,084 migraine cases identifies risk loci and subtype- specific risk alleles. Nat. Genet. 2022; 54: 152–160.
Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition// Cephalalgia. - 2018. - № 1 (38). - P. 1–211.ICHD-3, 2018.
Айата К., Лауритцен М. (2015) Распространение депрессии, распространение деполяризации и церебральная сосудистая система. Physiol Rev 95:953–993.
Ротрок, Дж. Ф., и Динер, Х. К. Головная боль, вызванная цереброваскулярными заболеваниями. Цефалгия. (2021) 41:479–92. doi: 10.1177/0333102421999045.
Yorns WR, Hardison HH: Mitochondrial dysfunction in migraine. Semin Pediatr Neurol. 2013, 20: 188-193.
Нестеровский Ю.Е., Заваденко Н.Н. Педиатрические аспекты мигрени в современной международной классификации головных болей III beta (2013) // РМЖ. 2017. № 13. С. 973–97847.
Кондратьева Н. С. //Характеристика молекулярно-генетических маркеров патогенеза мигрени Дисс. на уч. ст. канд. биолог. наук. МОСКВА 2017.
Долгорукова А.Н., Соколов А.Ю. Электрофизиологическая модель тригеминоваскулярной ноцицепции как инструмент экспериментального изучения фармакотерапии мигрени. Российский журнал боли. 2021;19(3):31–38. https://doi.org/10.17116/pain20211903131.
Gevirtz R. Non-pharmacologic aspects of pain, migraine and headaches. The role of the autonomic nervous system in headache: biomarkers and treatment. Curr. Pain Headache Rep. 2022; 26: 767–774.
Boćkowski L. Anti-inflammatory plasma cytokines in children and adolescents with migraine headaches/ L. Boćkowski, J. Smigielska- Kuzia, W. Sobaniec, B. Zelazowska-Rutkowska, W. Kułak, K.Sendrowski // Pharmacol Rep. 2010 Mar-Apr;62(2):287-91.
Алиджанова Д.А., Маджидова Ё.Н. //Клинические и иммунологические параллели течения первичных головных болей у детей. «Nevrologiya»—1(77), 2019.
Arruda M.A. Recent advances in the management of chronic migraine in children/ MA. Arruda, C.F. Chevis, M.E. Bigal // Expert Rev Neurother. 2018 Mar;18(3):231-239.
Popova V, Berk T. Pediatric Migraine – An Updated Review. US Neurology. 2019:15(2):68-73. doi: 10.17925/USN.2019.15.2.68.
Hershey AD, Winner P, Kabbouche MA, et al. Use of the ICHD-II criteria in the diagnosis of pediatric migraine. Headache. NovDec 2005;45(10):1288-97. doi: 10.1111/j.1526-4610.2005. 00260. X.
